Global Blood Therapeutics Inc (NASDAQ:GBT) insider Jung Choi sold 3,000 shares of the business’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $52.85, for a total value of $158,550.00. Following the transaction, the insider now directly owns 137,255 shares in the company, valued at approximately $7,253,926.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Jung Choi also recently made the following trade(s):
- On Monday, December 18th, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The stock was sold at an average price of $36.55, for a total value of $109,650.00.
Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) traded down $0.45 during trading on Thursday, hitting $53.00. The stock had a trading volume of 703,856 shares, compared to its average volume of 1,655,958. Global Blood Therapeutics Inc has a twelve month low of $14.70 and a twelve month high of $57.75. The firm has a market cap of $2,440.00 and a price-to-earnings ratio of -20.78.
Several institutional investors have recently made changes to their positions in GBT. BNP Paribas Arbitrage SA lifted its stake in shares of Global Blood Therapeutics by 694.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after purchasing an additional 3,975 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Global Blood Therapeutics in the 3rd quarter valued at $200,000. Trexquant Investment LP acquired a new position in shares of Global Blood Therapeutics in the 3rd quarter valued at $202,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Global Blood Therapeutics in the 3rd quarter valued at $205,000. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Global Blood Therapeutics in the 2nd quarter valued at $219,000. 85.72% of the stock is currently owned by institutional investors and hedge funds.
GBT has been the topic of a number of recent research reports. Oppenheimer set a $53.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Zacks Investment Research raised Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a research note on Tuesday, October 10th. Needham & Company LLC initiated coverage on Global Blood Therapeutics in a research note on Wednesday, September 20th. They set a “buy” rating and a $51.00 price objective on the stock. SunTrust Banks boosted their price objective on Global Blood Therapeutics to $67.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. Finally, BidaskClub raised Global Blood Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, November 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $62.07.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3144793/jung-choi-sells-3000-shares-of-global-blood-therapeutics-inc-gbt-stock.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.